PMID- 11499697
OWN - NLM
STAT- MEDLINE
DCOM- 20020115
LR  - 20191105
IS  - 0742-2091 (Print)
IS  - 0742-2091 (Linking)
VI  - 17
IP  - 2
DP  - 2001
TI  - Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
PG  - 67-75
AB  - Dendritic cells (DCs) can be used as an antigen presentation platform for 
      vaccination against cancer. In this approach, DCs are expanded in vitro from 
      monocyte-derived progenitors, and subsequently loaded with well-characterized 
      tumor-associated antigens (TAAs). TAAs can be incubated with DCs in various 
      forms, including peptides, recombinant proteins, plasmid DNA, formulated RNA, or 
      recombinant viruses. Advantages and limitations of DC-based cellular vaccines 
      against cancers, as well as preliminary results of clinical studies already 
      performed in humans, are discussed. Importantly, significant advances in our 
      understanding of the biology of DCs can be used to support the design of new 
      vaccines or adjuvants in order to elicit TH1 cellular immune responses.
FAU - Burdin, N
AU  - Burdin N
AD  - Departement Recherche et Developpement, Aventis Pasteur, Marcy l'Etoile, France.
FAU - Moingeon, P
AU  - Moingeon P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Cell Biol Toxicol
JT  - Cell biology and toxicology
JID - 8506639
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology/metabolism
MH  - Humans
MH  - Neoplasms/*therapy
MH  - T-Lymphocytes/immunology
RF  - 53
EDAT- 2001/08/14 10:00
MHDA- 2002/01/16 10:01
CRDT- 2001/08/14 10:00
PHST- 2001/08/14 10:00 [pubmed]
PHST- 2002/01/16 10:01 [medline]
PHST- 2001/08/14 10:00 [entrez]
AID - 10.1023/a:1010944003649 [doi]
PST - ppublish
SO  - Cell Biol Toxicol. 2001;17(2):67-75. doi: 10.1023/a:1010944003649.